Company Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.
The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015.
Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2009 |
| IPO Date | May 3, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Dr. Anirvan Ghosh Ph.D. |
Contact Details
Address: 285 East Grand Avenue South San Francisco, California 94080 United States | |
| Phone | (650) 416-1192 |
| Website | unitybiotechnology.com |
Stock Details
| Ticker Symbol | UBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001463361 |
| CUSIP Number | 91381U101 |
| ISIN Number | US91381U2006 |
| Employer ID | 26-4726035 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anirvan Ghosh Ph.D. | Chief Executive Officer and Director |
| Dr. Nathaniel E. David A.B., Ph.D. | Co-Founder and Executive Director |
| Lynne Marie Sullivan | Chief Financial Officer and Head of Corporate Development |
| Dr. Jan M. van Deursen | Founder |
| Dr. Judith Campisi Ph.D. | Founder |
| Daohong Zhou M.D. | Founder |
| Alexander Azoy | Chief Accounting Officer and Principal Accounting Officer |
| Dr. Przemyslaw Sapieha Ph.D. | Chief Scientist |
| Alexander Hieu Nguyen J.D. | General Counsel and Corporate Secretary |
| Sharon Klier M.D., M.P.H. | Head of Ophthalmology and Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 15, 2024 | 10-K | Annual Report |
| Apr 15, 2024 | 8-K | Current Report |
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |